Single-chain lipopeptide vaccines for the induction of virus-specific cytotoxic T cell responses in randomly selected populations.
Effective vaccine development is now taking advantage of the rapidly accumulating information concerning the molecular basis of a protective immune response. Analysts and medicinal chemists have joined forces with immunologists and taken up the clear challenge of identifying immunologically active structural elements and synthesizing them in pure, reproducible forms. Current literature reveals the growing interest for extremely reductionist approaches aiming at producing totally synthetic vaccines that would be fully defined at the molecular level and particularly safe. The sequential information contained in these formulations tends to be minimized to those epitopes which elicit neutralizing antibodies, or cell-mediated responses. In the following review, we describe some of our results in developing fully synthetic, clinically acceptable lipopeptide vaccines for inducing cytotoxic T lymphocytes (CTL) responses in randomly selected populations.
Gras-Masse
H
H
UMR 8525, Institut de Biologie de Lille, Pasteur de Lille, 1 rue Calmette, 59021 Cedex, Lille, France. helen.gras@pateur-lille.fr
D000956:Antigens, Viral / Q000276:immunology; D006801:Humans; D008074:Lipoproteins / Q000737:chemistry / Q000276:immunology; D010455:Peptides / Q000737:chemistry* / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology* / Q000627:therapeutic use*; D014777:Virus Diseases / Q000276:immunology* / Q000517:prevention & control*
D000956:Antigens, Viral; D008074:Lipoproteins; D010455:Peptides; D022223:Vaccines, Subunit